Allogeneic adipose stem cell therapy in acute myocardial infarction

Rigol, Montserrat; Solanes, Núria; Roura, Santiago; Roqué, Mercè; Novensá, Laura; Dantas, Ana Paula; Martorell, Jaume; Sitges, Marta; Ramírez, José; Bayés‐Genís, Antoni; Heras, Magda

doi:10.1111/eci.12195

Cited by 49 publications

(59 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like stem cells obtained from bone tissues, Adipose Tissue-derived Stem Cells (ADMSC) collection is free of ethical concerns and is associated with other pluses (Fig. 1), namely its greater handiness, the minimally invasive nature of collection, the easy and rapid in vitro expansion and the ability to differentiate into distinct lineages, such as cardiac cells [34][35][36][37][38][39][40][41]. Although broadly accepted as immune-privileged, it has been shown that ADMSCs elicit an immune response in vivo [34].…”

Section: Adipose Tissue-derived Stem Cellsmentioning

confidence: 99%

“…The advantages and limitations of each stem cell with regard to the possible emergence of ethical concerns (symbolized by ¥), the invasiveness and collection (from + to ++++), the isolation procedure, the abundance (from + to ++++), expansion and proliferation rate, the transdifferentiation capacity, the paracrine effects or/and cardiomyogenic potential, the survival and engraftment capacity as well as the immunogenic, oncogenic or teratogenic risks is given in the accessory side tables. The left table abridges bone marrow-derived stem cells [3,[19][20][21]27,28], cortical bone-derived stem cells [32,33], adipose tissue-derived stem cells [34,37,39,41] and gestation-related stem cells [42][43][44][45][46][47][48][49]51,54] and the right table abridges cardiac stem cells [57,59,60], skeletal muscle stem cells [62,63,66] and induced pluripotent stem cells [67,[69][70][71]. The human body scheme was constructed with images sourced from Servier Medical Art (http://www.servier.com/ Powerpoint-image-bank) and Cientic website (http://www.cientic.com/).…”

Section: Adipose Tissue-derived Stem Cellsmentioning

confidence: 99%

“…the absence of signs of myocardial structural and functional recovery [15,34,44,45,62,71,75] or the manifestation of adverse outcomes, such as arrhythmia [36]. These can be surpassed mainly by one of three alternatives, namely by electing a different stem cell type, by refining a population of stem cells or by adjusting the cell dosage/number of administrations (Box 3, Fig.…”

Section: Cell Choice Refinement Dosage and Timing Of Administrationmentioning

confidence: 99%

“…[21,57,58,61,111]) of cells but ICI (e.g. [15,30,34,76,102]), intravenous (IVI, [44,54]) and intramuscular injections [46] and epicardial delivery (e.g. [17,53,[64][65][66]) are routes of choice, too.…”

Section: Clinical Translationmentioning

confidence: 99%

“…The final, yet the most compromising, issue in clinical translation is related to the therapy monitoring, particularly the molecular analysis, which is performed post-mortem in animal models by, for instance, histological and immunohistochemical analysis as well as by PCR and western blot techniques making use of heart tissue samples [3,8,15,16,21,22,29,34,38,41,51,54,61,62,64,105,109,110,119]. Only Chen et al [103].…”

Section: Clinical Translationmentioning

confidence: 99%

See 4 more Smart Citations

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Trindade

Leite‐Moreira

Ferreira-Martins

et al. 2017

International Journal of Cardiology

View full text Add to dashboard Cite

Today there is an increasing demand for heart transplantations for patients diagnosed with heart failure. Though, shortage of donors as well as the large number of ineligible patients hurdle such treatment option. This, in addition to the considerable number of transplant rejections, has driven the clinical research towards the field of regenerative medicine. Nonetheless, to date, several stem cell therapies tested in animal models fall by the wayside and when they meet the criteria to clinical trials, subjects often exhibit modest improvements. A main issue slowing down the admission of such therapies in the domain of human trials is the lack of protocol standardization between research groups, which hampers comparison between different approaches as well as the lack of thought regarding the clinical translation. In this sense, given the large amount of reports on stem cell therapy studies in animal models reported in the last 3 years, we sought to evaluate their advantages and limitations towards the clinical setting and provide some suggestions for the forthcoming investigations. We expect, with this review, to start a new paradigm on regenerative medicine, by evoking the debate on how to plan novel stem cell therapy studies with animal models in order to achieve more consistent scientific production and accelerate the admission of stem cell therapies in the clinical setting.

show abstract

Section: Adipose Tissue-derived Stem Cellsmentioning

confidence: 99%

Section: Adipose Tissue-derived Stem Cellsmentioning

confidence: 99%

Section: Cell Choice Refinement Dosage and Timing Of Administrationmentioning

confidence: 99%

Section: Clinical Translationmentioning

confidence: 99%

Section: Clinical Translationmentioning

confidence: 99%

See 3 more Smart Citations

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Trindade

Leite‐Moreira

Ferreira-Martins

et al. 2017

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

The anti‐inflammatory effects of mesenchymal stem cells attenuate diffuse pulmonary hemorrhage

Guan,

Chen,

et al. 2023

Biotechnology Journal

View full text Add to dashboard Cite

There are few effective treatment options for diffuse pulmonary hemorrhage (DPH). We aimed to elucidate the therapeutic role and underlying mechanisms of mesenchymal stem cells (MSCs) and MSC‐derived extracellular vesicles (MSC‐EVs) in DPH. Therapeutic effects of MSCs/MSC‐EVs in pristane‐induced DPH mice were evaluated via pulmonary function testing and histopathology. Transcriptome sequencing analyzed differentially expressed genes in control, DPH, and MSC groups. The proportion of macrophage polarization was evaluated in vivo and in vitro via fluorescence‐activated cell sorting in control, DPH, MSC, MSC‐EV inhalation, and MSC‐EV intravenous groups. Intraperitoneal injection of pristane induced diffuse alveolar hemorrhage, early fibrosis, and inflammation in C57BL/6 mice. Monocytes were depleted in the peripheral blood in DPH mice and MSCs were recruited to the lungs, resulting in significantly attenuated diffuse alveolar hemorrhage and suppressed immunological response. This was more effective in the hyperacute hemorrhage phase than the early inflammatory phase. An MSC treatment‐mediated anti‐inflammatory effect was observed in DPH mice. Furthermore, MSC‐EVs inhalation or tail‐vein injection could effectively reduce DPH injury. MSCs could suppress macrophage M1 polarization in DPH in vivo and in vitro. MSCs displayed significant therapeutic effects in pristane‐induced DPH, which may be a promising cell‐free therapeutic approach.This article is protected by copyright. All rights reserved

show abstract

Synergistic effect of bioactive lipid and condition medium on cardiac differentiation of human mesenchymal stem cells from different tissues

Jiang

Wang

Pan

et al. 2016

Cell Biochemistry & Function

View full text Add to dashboard Cite

Human umbilical cord mesenchymal stem cells (hUCMSCs) and human adipose tissue mesenchymal stem cells (hATMSCs) have the potential to differentiate into cardiomyocytes, making them promising therapeutic candidates for treating damaged cardiac tissues. Currently, however, the differentiated cells induced from hUCMSCs or hATMSCs can hardly display functional characteristics similar to cardiomyocytes. In this study, we have investigated the effects of bioactive lipid sphingosine‐1‐phosphate (S1P) on cardiac differentiations of hUCMSCs and hATMSCs in condition medium composed of cardiac myocytes culture medium or 5‐azacytidine. Cardiac differentiations were identified through immunofluorescence staining, and the results were observed with fluorescence microscopy and confocal microscopy. Synergistic effects of S1P and condition medium on cell viability were evaluated by MTT assays. Functional characteristics similar to cardiomyocytes were evaluated through detecting calcium transient. The differentiated hUCMSCs or hATMSCs in each group into cardiomyocytes showed positive expressions of cardiac specific proteins, including α‐actin, connexin‐43 and myosin heavy chain‐6 (MYH‐6). MTT assays showed that suitable differentiation time was 14 days and that the optimal concentration of S1P was 0.5 μM. Moreover, incorporation of S1P and cardiac myocytes culture medium gave rise to calcium transients, an important marker for displaying in vivo electrophysiological properties. This feature was not observed in the S1P‐5‐azacytidine group, indicating the possible lack of cellular stimuli such as transforming growth factor‐beta, TGF‐β. © 2016 The Authors. Cell Biochemistry and Function published by John Wiley & Sons, Ltd.

show abstract

Allogeneic adipose stem cell therapy in acute myocardial infarction

Cited by 49 publications

References 33 publications

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

The anti‐inflammatory effects of mesenchymal stem cells attenuate diffuse pulmonary hemorrhage

Synergistic effect of bioactive lipid and condition medium on cardiac differentiation of human mesenchymal stem cells from different tissues

Contact Info

Product

Resources

About